Evidence map›Paper›PMID 37048119›Full record

ArticleCells2023

Mesenchymal Stem/Stromal Cells Derived from Cervical Cancer Promote M2 Macrophage Polarization.

Víctor Adrián Cortés-Morales, Luis Chávez-Sánchez, Leticia Rocha-Zavaleta, Sandra Espíndola-Garibay, Alberto Monroy-García, Marta Elena Castro-Manrreza, Guadalupe Rosario Fajardo-Orduña, Teresa Apresa-García, Marcos Gutiérrez-de la Barrera, Héctor Mayani and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Víctor Adrián Cortés-MoralesMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.ORCID 0000-0002-3331-7309
Luis Chávez-SánchezImmunology Medical Research Unit, Pediatric Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.
Leticia Rocha-ZavaletaDepartamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico.ORCID 0000-0002-3801-5393
Sandra Espíndola-GaribayImmunology Medical Research Unit, Pediatric Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.
Alberto Monroy-GarcíaImmunology and Cancer Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.ORCID 0000-0002-9733-9013
Marta Elena Castro-ManrrezaImmunology and Stem Cells Laboratory, Multidisciplinary Unit of Experimental Research Zaragoza, FES, Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.ORCID 0000-0002-7098-9905
Guadalupe Rosario Fajardo-OrduñaMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.ORCID 0000-0002-1001-4073
Teresa Apresa-GarcíaOncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.
Marcos Gutiérrez-de la BarreraOncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.
Héctor MayaniHematopoietic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.
Juan José MontesinosMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico.ORCID 0000-0002-1042-3205
Mexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages with the M2 phenotype promote tumor development through the immunosuppression of antitumor immunity. We previously demonstrated the presence of mesenchymal stem/stromal cells (MSCs) in cervical cancer (CeCa-MSCs), suggesting an immune protective capacity in tumors, but to date, their effect in modulating macrophage polarization remains unknown. In this study, we compared the capacities of MSCs from normal cervix (NCx) and CeCa to promote M2 macrophage polarization in a coculture system. Our results demonstrated that CeCa-MSCs, in contrast to NCx-MSCs, significantly decreased M1 macrophage cell surface marker expression (HLA-DR, CD80, CD86) and increased M2 macrophage expression (CD14, CD163, CD206, Arg1) in cytokine-induced CD14

Indexed as

Interleukin-10Uterine Cervical NeoplasmsCytokinesFemaleHumansMacrophagesStromal CellsCytokinesInterleukin-10cervical cancerimmunoregulationmacrophage polarizationtumor-derived mesenchymal stem/stromal cells

Identifiers

PMID37048119
PMCPMC10093665
OpenAlexW4361279890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.